<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
To expand its footprint in eye care, AbbVie Inc.( ABBV , Financial) has struck a billion-dollar deal to gain access to a gene therapy used to treat several common kinds of eye disease. The Chicago-area pharma giant announced Monday that it will be collaborating with Regenxbio Inc. ( RGNX , Financial) on the Maryland-based drugmaker’s treatment called RGX-314.
...read full article on GuruFocus
